Hologic, Inc. (NASDAQ:HOLX) Position Trimmed by California Public Employees Retirement System

California Public Employees Retirement System reduced its holdings in Hologic, Inc. (NASDAQ:HOLX) by 0.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,086,141 shares of the medical equipment provider’s stock after selling 4,698 shares during the quarter. California Public Employees Retirement System owned approximately 0.48% of Hologic worth $78,300,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Benson Investment Management Company Inc. bought a new position in Hologic in the fourth quarter worth about $4,832,000. Principal Financial Group Inc. raised its position in shares of Hologic by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock worth $19,547,000 after purchasing an additional 1,606 shares during the period. Clean Yield Group lifted its holdings in shares of Hologic by 18.9% in the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after purchasing an additional 7,266 shares during the last quarter. Janus Henderson Group PLC boosted its position in Hologic by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after purchasing an additional 800 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in Hologic by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after buying an additional 238,222 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

NASDAQ:HOLX opened at $61.77 on Tuesday. The company has a 50-day moving average of $65.08 and a 200-day moving average of $73.11. The firm has a market cap of $13.86 billion, a price-to-earnings ratio of 19.49, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HOLX shares. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a report on Monday, February 3rd. Jefferies Financial Group assumed coverage on shares of Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price for the company. Citigroup dropped their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, Wolfe Research assumed coverage on Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.